2022 World Conference on Lung Cancer (ePosters)-EP14.01-015. IMforte: A Phase III Study of Lurbinectedin and Atezolizumab Versus Atezolizumab as Maintenance Therapy in ES-SCLC

EP14.01-015. IMforte: A Phase III Study of Lurbinectedin and Atezolizumab Versus Atezolizumab as Maintenance Therapy in ES-SCLC

Back to course

Pdf Summary

The document is a poster providing information about a clinical trial design for the study called IMforte, which aims to evaluate the efficacy and safety of lurbinectedin and atezolizumab as maintenance therapy in extensive stage small-cell lung cancer (ES-SCLC). The study is sponsored by F. Hoffmann-La Roche, Ltd.<br /><br />The poster acknowledges the participants and their families, as well as the investigators and clinical study sites involved in the trial. Medical writing support for the poster was provided by Marcia Gamboa, funded by F. Hoffmann-La Roche, Ltd.<br /><br />The rationale for combining atezolizumab and lurbinectedin is discussed. Atezolizumab is an anti-PD-L1 antibody that has shown effectiveness in combination with platinum-based chemotherapy as a first-line treatment for ES-SCLC. However, patients often experience disease progression. Lurbinectedin is a selective inhibitor of oncogenic transcription that induces DNA double-strand breaks, leading to apoptosis.<br /><br />The IMforte study aims to enroll approximately 690 participants from 13 countries. The study design includes an induction phase where participants receive four cycles of atezolizumab plus carboplatin and etoposide. After the induction phase, eligible participants are randomized to receive either atezolizumab plus lurbinectedin or atezolizumab alone as maintenance therapy.<br /><br />The primary endpoints of the study are progression-free survival (PFS) and overall survival (OS). Secondary endpoints include investigator-assessed PFS, objective response rate, duration of response, incidence and severity of adverse events, and quality of life.<br /><br />The poster also provides information on the author affiliations and disclosures.<br /><br />Further information on the IMforte trial can be found at the provided clinical trials website link.

Asset Subtitle

Luis Paz-Ares

Meta Tag

Speaker Luis Paz-Ares

Topic Small Cell Lung Cancer and Neuro-endocrine Tumours - Informing ES-SCLC

Keywords

clinical trial design

IMforte

lurbinectedin

atezolizumab

maintenance therapy

ES-SCLC

F. Hoffmann-La Roche Ltd.

induction phase

progression-free survival

overall survival